Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022

BUY
$12.59 - $18.8 $3.15 Million - $4.7 Million
250,000 New
250,000 $4.37 Million
Q1 2021

May 17, 2021

SELL
$14.17 - $19.11 $2.83 Million - $3.81 Million
-199,600 Closed
0 $0
Q4 2020

Feb 16, 2021

BUY
$11.9 - $20.91 $2.38 Million - $4.17 Million
199,600 New
199,600 $3.17 Million

Others Institutions Holding KDNY

About CHINOOK THERAPEUTICS, INC.


  • Ticker KDNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,896,300
  • Description
  • Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...
More about KDNY
Track This Portfolio

Track Ally Bridge Group (Ny) LLC Portfolio

Follow Ally Bridge Group (Ny) LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ally Bridge Group (Ny) LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ally Bridge Group (Ny) LLC with notifications on news.